No Data
Peijia Medical Completes First Compassionate Use Treatment of Aortic Valve Replacement Device
Peijia Medical-B (09996.HK): Successfully completed the first compassionate use of the TaurusTrioTM TAVR system in Hong Kong.
Gelonghui, November 18th丨Paijia Medical -B (09996.HK) announced that recently, the group's product TaurusTrioTM for treating symptomatic severe aortic regurgitation ("AR") through the transcatheter aortic valve replacement ("TAVR") system has successfully completed the first compassionate use case in Hong Kong, China. In January 2024, the company has completed patient enrollment for the multicenter registration clinical trial of TaurusTrioTM TAVR system being conducted in China. Follow-up assessments in the subsequent stages are underway. The company expects to commercialize this product in China after obtaining regulatory approval.
Peijia Medical-B (09996.HK): Yu Zhiyun resigns as a non-executive director.
Glory November 1st | Peijia Medical - B (09996.HK) announced that Yu Zhiyun resigned as a non-executive director and a member of the board of directors' remuneration committee, effective immediately on November 1, 2024. Yu Zhiyun resigned from his position to devote more time to other work matters. Yu Zhiyun will continue to serve as a company consultant.
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Biomedical stocks are performing strongly. Lai Kai Medicine (02105) rose by 26.26%, institutions pointed out that the sector's valuation has reached a historical low, still with further room for recovery.
Golden Finance News | Biomedical stocks are strong, with LaiKai Pharmaceutical (02105) up 26.26%, AmyMed Vaccine (06660) up 19.76%, YimingAngke (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, Hutchmed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%. Bocom Intl stated that the tenth batch of National Drug Centralized Procurement Volume Document shows the highest historical threshold for this round of national procurement, the highest proportion of injections in history, and expects the competition to be exceptionally fierce, but for
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion in 4 years.
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some Risk
